Somatic gene transfer into the lactating ovine mammary gland

Disease resistance for different livestock species

This chapter deals with progress in disease resistance for the livestock population species-wise and describes the progress that occurred globally. Certain genes were identified for mastitis resistance and the strategies for genomic control of mastitis are discussed. Gene-edited tuberculosis-resistant cattle were developed for the first time with CRISPR/Cas 9 technology with NRAMP gene insert. Similarly studies are in progress for the development of trypanosomiasis-resistant cattle at ILRI. Genomic insights were discussed for disease resistance for goat against gastrointestinal nematode infestation, coccidiosis, peste des petits ruminants, and scrapie. Similarly genomic resistance was also discussed for sheep, discussing the mechanism of disease resistance with MHC, antibody and T cell response, cytokines, and receptors. Genes identified for bacterial diarrhoeal resistance as K88, F18 (an intestinal receptor) for resistance to bacterial infection in pig. Gene-edited pigs were developed against porcine reproductive and respiratory syndrome and transmissible gastroenteritis caused by corona virus using CRISPR/Cas9 technology. Insights on the omics technologies developed and studied were discussed for livestock species. Genomic control on various diseases of poultry is discussed as salmonellosis, avian influenza, Marek’s disease, Newcastle disease with advanced genomic and allied techniques for its control as RNA interference, flow cytometry, quantitative polymerase chain reaction, transcriptomics, etc. A new concept on natural antibodies was discussed.

Adeno-associated-virus-mediated transduction of the mammary gland enables sustained production of recombinant proteins in milk

Biopharming for the production of recombinant pharmaceutical proteins in the mammary gland of transgenic animals is an attractive but laborious alternative compared to mammalian cell fermentation. The disadvantage of the lengthy process of genetically modifying an entire animal could be circumvented with somatic transduction of only the mammary epithelium with recombinant, replication-defective viruses. While other viral vectors offer very limited scope for this approach, vectors based on adeno-associated virus (AAV) appear to be ideal candidates because AAV is helper-dependent, does not induce a strong immune response and has no association with disease. Here, we sought to test the suitability of recombinant AAV (rAAV) for biopharming. Using reporter genes, we showed that injected rAAV efficiently transduced mouse mammary cells. When rAAV encoding human myelin basic protein (hMBP) was injected into the mammary glands of mice and rabbits, this resulted in the expression of readily detectable protein levels of up to 0.5 g/L in the milk. Furthermore we demonstrated that production of hMBP persisted over extended periods and that protein expression could be renewed in a subsequent lactation by re-injection of rAAV into a previously injected mouse gland.

Efficiency of human lactoferrin transgenic donor cell preparation for SCNT

The combination of somatic cell nuclear transfer (SCNT) and transgenic technology leads to the production of transgenic cloned animals, wherein the preparation of competent transgenic donor cells is the pivotal upstream step. The purpose of this study was to establish an efficient procedure to prepare human lactoferrin (hLTF) transgenic donor cells for SCNT. Thus, two cell culture systems were employed: caprine mammary epithelial cells (for evaluation of the hTLF transgenic expression in vitro), and fetal-derived fibroblast cells (for identification of competent transgenic donor cells). Induced by hormonal signals, recombinant hLTF was detected in the supernatant of transfected mammary epithelial cells by Western blot. Reliable hLTF transgenic fibroblast cell clones were identified by screening with multiple PCR amplification, EGFP fluorescence, and chromosomal counting (32.5+/-2.3%). This study may provide an effective upstream system to prepare SCNT donor cells for the production of human recombinant pharmaceuticals from the milk of transgenic animals.

Femtosecond infrared laser-an efficient and safe in vivo gene delivery system for prolonged expression

The major advantages of "naked DNA gene therapy" are its simplicity and a low or negligible immune response. Gene delivery by DNA electroporation (EP) involves injection of DNA and the application of a brief electric pulse to enhance cellular permeability. Although EP is an efficient gene transduction technique in rodents, it requires much higher voltages (>500 V) in larger animals, and hence, in practice it would be hazardous for human patients, as it would cause serious tissue damage. To overcome the obstacles associated with EP-mediated gene delivery in vivo, we developed a new method of gene transduction that uses laser energy. The femtosecond infrared titanium sapphire laser beam was developed specifically for enhancing in vivo gene delivery without risks of tissue damage. System optimization revealed that injection of 10 micro g naked DNA into the tibial muscle of mice followed by application of the laser beam for 5 s, focused to 2 mm depth upon an area of 95 x 95 micro m(2), resulted in the highest intensity and duration of gene expression with no histological or biochemical evidence of muscle damage. We assessed the potential clinical application of LBGT technology by using it to transfer the murine erythropoietin (mEpo) gene into mice. LBGT-mediated mEpo gene delivery resulted in elevated (>22%) hematocrit levels that were sustained for 8 weeks. Gene expression following LBGT was detected for >100 days. Hence, LBGT is a simple, safe, effective, and reproducible method for therapeutic gene delivery with significant clinical potential.